Agilent MMR IHC Panel pharmDx (Dako Omnis) Receives FDA Approval as a Companion Diagnostic Test for Colorectal Cancer
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion diagnostic (CDx) test for colorectal cancer. This test aids in identifying mismatch repair deficient (dMMR) colorectal cancer (CRC) patients who are eligible for treatment with Bristol Myers Squibb’s Opdivo® (nivolumab) alone or Opdivo (nivolumab) in combination with Yervoy® (ipilimumab). The MMR IHC Panel pharmDx (Dako Om
Related Questions
How will the FDA approval of Agilent's MMR IHC Panel pharmDx affect Agilent's stock valuation and market sentiment?
What competitive advantage does this companion diagnostic give Agilent compared to other IHC panel providers and how might it influence market share?
How might this approval impact the revenue outlook for both Agilent and Bristol Myers Squibb's immunotherapy products targeting dMMR colorectal cancer?